Using our published DHCR24 inhibitor SH42 (Muller et al, 2017), we aimed to investigate the potential therapeutic effects of DHCR24 inhibition on diet‐induced NAFLD development in APOE*3‐Leiden.CETP mice, a well‐established humanized mouse model for the study of (cardio)metabolic diseases. This evidence concerns the gene CETP and metabolic dysfunction-associated steatotic liver disease.